SAVANNAH, GA--(INFOLINK)--Mar. 01, 2005--Health Discovery Corporation (OTC BB: HDVY) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for its patent application covering the use of recursive feature elimination (RFE) in support vector machines (SVMs). RFE is a process by which key features of input data can be identified as being more significant for use in classifying the data using a support vector machine. Feature selection methods are critical in reducing processor run time when analyzing the high volumes of data encountered with gene expression data and related information for discovery of biomarkers. By eliminating those features that are either duplicative or non-critical to the successful classification of the data, accuracy is improved and considerable timesavings are achieved during processing. The use of SVMs for analysis of gene expression data represents a significant improvement over existing analytical methods because it recognizes the interdependence of gene expression response among genes that are affected by the target disease. The addition of RFE further advances the value of SVM methods in biological discovery.
In addition to the allowed patent application, Health Discovery Corporation's SVM patent portfolio includes 9 issued U.S. and foreign patents covering applications of support vector machines for discovery of knowledge from large data sets. The issued patents cover methods and systems for pre-processing of data to enhance knowledge discovery using SVMs, analysis of data using multiple support vector machines and for multiple data sets, and providing SVM analysis services over the Internet. HDC's pending U.S. and foreign patent applications cover numerous improvements to and applications of SVMs, including computer-aided image analysis using SVMs, with particular application to diagnosis using medical images, methods of feature selection for enhanced SVM efficiency and biomarkers for colon cancer, prostate cancer and renal cancer discovered with these methods, and use of SVMs for analysis of spectral data such as data generated in mass spectrometry.
The original scientific publication introducing Recursive Feature Elimination (RFE) in Support Vector Machines (SVMs) was co-authored by Health Discovery Corporation's Chairman and CEO, Dr. Stephen D. Barnhill, and two members of Health Discovery Corporation's Scientific Team -- Dr. Vladimir Vapnik and Dr. Isabelle Guyon. This original paper can be read at http://www.kyb.tuebingen.mpg.de/bs/people/weston/GENESEL.PDF.
Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation, commented, "I am very excited that the United States Patent and Trademark Office has issued a Notice of Allowance for this very important patent in our Company's intellectual property portfolio." Dr. Barnhill continued, "Recursive Feature Elimination Support Vector Machines have been shown in independent studies to be a very important tool for proteomic and genomic biomarker discovery and I am proud that members of Health Discovery Corporation's Scientific Team played a critical role in its development."
Health Discovery Corporation is a systems biology-oriented biomarker and pathway discovery company, which provides all aspects of First-Phase Biomarker Discovery(sm). The Company was established to provide pharmaceutical and diagnostic companies worldwide with newly discovered biomarkers used to create more accurate diagnostic tests, novel drug targets for more personalized medicines and new methods for detecting patients "at-risk" for toxicity-related events, thereby providing safer medications. Founded in September 2003, the Company is headquartered in Savannah, GA. For more information contact: Stephen D. Barnhill, M.D. of Health Discovery Corporation, 1-800-965-3198 or barnhillmd@sprynet.com.
This news release contains "forward-looking statements" within the meaning of Section 27A of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.
CONTACT: Stephen D. Barnhill, M.D.
+1-800-965-3198
barnhillmd@sprynet.com
www.healthdiscoverycorp.com
